Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2022

14-07-2022 | Graft-Versus-Host Disease | Letter to the Editor

Prognostic impact of switching from cyclosporine to corticosteroids early after single cord blood transplantation

Authors: Kosuke Takano, Takaaki Konuma, Maki Monna-Oiwa, Masamichi Isobe, Seiko Kato, Satoshi Takahashi, Yasuhito Nannya

Published in: Annals of Hematology | Issue 10/2022

Login to get access

Excerpt

Dear Editor, …
Appendix
Available only for authorised users
Literature
1.
Yasu T, Konuma T, Oiwa-Monna M, Kato S, Tanoue S, Isobe M, Mizusawa M, Kuroda S, Takahashi S, Tojo A (2018) Efficacy and safety of low-dose liposomal amphotericin B in adult patients undergoing unrelated cord blood transplantation. Antimicrob Agents Chemother 62:e01205-e1218PubMedPubMedCentral
2.
Kishi Y, Kami M, Miyakoshi S, Kanda Y, Murashige N, Teshima T, Kusumi E, Hara S, Matsumura T, Yuji K, Masuoka K, Wake A, Morinaga S, Kanemaru M, Hayashi T, Tanaka Y, Taniguchi S (2005) Tokyo Stem Cell Transplant Consortium Early immune reaction after reduced-intensity cord-blood transplantation for adult patients. Transplantation 80:34–40CrossRef
3.
Konuma T, Ooi J, Nagayama H, Tomonari A, Tsukada N, Kato S, Kawakita T, Isobe M, Monna-Oiwa M, Tojo A, Iseki T, Takahashi S (2022) Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies. Ann Hematol 101:177–189CrossRef
4.
Konuma T, Kato S, Isobe M, Mizusawa M, Oiwa-Monna M, Takahashi S, Tojo A (2019) Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose total body irradiation/granulocyte colony-stimulating factor-combined cytarabine in single cord blood transplantation for elderly patients with nonremission myeloid malignancies. Biol Blood Marrow Transplant 25:764–770CrossRef
5.
Mizusawa M, Konuma T, Kato S, Isobe M, Shibata H, Suzuki M, Takahashi O, Oiwa-Monna M, Takahashi S, Tojo A (2020) Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation. Int J Hematol 111:858–868CrossRef
6.
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458CrossRef
7.
Kanunnikov MM, Rakhmanova ZZ, Levkovsky NV, Vafina AI, Goloshapov OV, Shchegoleva TS, Vlasova JJ, Paina OV, Morozova EV, S Zubarovskaya L, Kulagin AD, S Moiseev I (2021) Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy. Clin Transplant 35:e14180
8.
Sayer HG, Klink A, Schenk T, Treschl A, Schilling K, Hochhaus A (2010) Safety and efficacy of the mTOR inhibitor everolimus as early interventional replacement for calcineurin inhibitors in graft-versus-host disease (GvHD) prophylaxis after allogeneic stem cell transplantation. Blood 116:960–961CrossRef
9.
Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Yu J, Wei G, Huang H (2020) Calcineurin inhibitors replacement by ruxolitinib as graft-versus-host disease prophylaxis for patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 26:e128–e133CrossRef
10.
Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M (2006) Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 38:445–451CrossRef
Metadata
Title
Prognostic impact of switching from cyclosporine to corticosteroids early after single cord blood transplantation
Authors
Kosuke Takano
Takaaki Konuma
Maki Monna-Oiwa
Masamichi Isobe
Seiko Kato
Satoshi Takahashi
Yasuhito Nannya
Publication date
14-07-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04916-6

Other articles of this Issue 10/2022

Annals of Hematology 10/2022 Go to the issue

Letter to the Editor

Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation

Original Article

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Original Article

Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis

Original Article

Clinical characteristics and treatment of NK/T-cell lymphoma–associated HLH

Review Article

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

Original Article

Amyloidosis and COVID-19: experience from an amyloid program in Canada
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits